MCID: BCT002
MIFTS: 52

Bacterial Vaginosis

Categories: Reproductive diseases

Aliases & Classifications for Bacterial Vaginosis

MalaCards integrated aliases for Bacterial Vaginosis:

Name: Bacterial Vaginosis 12 75 55 3 15 63 17 72
Vaginosis, Bacterial 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3385
MeSH 44 D016585
NCIt 50 C116973
SNOMED-CT 68 85569008
UMLS 72 C0085166

Summaries for Bacterial Vaginosis

PubMed Health : 63 About bacterial vaginosis: In bacterial vaginosis (sometime abbreviated as BV) much larger numbers of bacteria grow inside of the vagina than would normally just be there. This increase in bacteria is usually not dangerous and it often goes unnoticed, but it can cause a strong-smelling vaginal discharge and be very unpleasant. It also increases the risk of a vaginal infection. Antibiotics can provide effective treatment.

MalaCards based summary : Bacterial Vaginosis, also known as vaginosis, bacterial, is related to trichomoniasis and cervicitis. An important gene associated with Bacterial Vaginosis is PEPD (Peptidase D), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Cranberry and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and cervix, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis.

CDC : 3 Bacterial vaginosis (BV) is a condition that happens when there is too much of certain bacteria in the vagina. This changes the normal balance of bacteria in the vagina.

Wikipedia : 75 Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common... more...

Related Diseases for Bacterial Vaginosis

Diseases related to Bacterial Vaginosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 trichomoniasis 32.2 LAP3 CXCL8
2 cervicitis 31.4 DEFB4A CXCL8
3 endometritis 31.3 TNF IL6 IL1B
4 vaginitis 31.3 PRF1 LAP3 IL6 IL1B DEFB4A CXCL8
5 preterm premature rupture of the membranes 31.0 IL6 IL1B CXCL8
6 placenta disease 30.8 IL6 IL1B CXCL8
7 endometriosis 30.3 IL6 IL1B CXCL8
8 funisitis 30.2 IL6 IL1B CXCL8
9 chlamydia 30.1 TNF TLR4 IL6 IL1B IL1A CXCL8
10 scabies 30.1 MBL2 IL1A CXCL8
11 oral candidiasis 30.0 IL1A DEFB4A CXCL8
12 acquired immunodeficiency syndrome 30.0 TNF IL6 IL1B
13 peritonitis 29.9 TNF IL6 IL1B CXCL8
14 cytomegalovirus infection 29.6 TNF IL6 IL1B CXCL8
15 cerebral palsy 29.6 TNF MBL2 IL6 IL1B
16 chorioamnionitis 29.6 TNF TLR4 IL6 IL1B IL1A CXCL8
17 cystitis 29.6 TNF TLR4 IL6 CXCL8
18 cystic fibrosis 29.4 TLR4 MBL2 DEFB4A CXCL8
19 osteoporosis 29.3 TNF IL6 IL1B IL1A
20 toxic shock syndrome 29.2 TNF TLR4 IL6 IL1B CXCL8
21 lung disease 28.9 TNF MBL2 IL6 IL1B CXCL8
22 vaginal disease 28.9 PRF1 LAP3 IL6 IL1B DEFB4A CXCL8
23 periodontitis 28.5 TNF TLR4 IL6 IL1B IL1A CXCL8
24 bacterial infectious disease 28.2 TNF TLR4 MBL2 IL6 IL1B DEFB4A
25 vaginal discharge 11.9
26 candidiasis 10.9
27 pelvic inflammatory disease 10.9
28 overgrowth syndrome 10.8
29 vulvovaginal candidiasis 10.7
30 syphilis 10.7
31 infertility 10.6
32 cervix uteri carcinoma in situ 10.6
33 cervical intraepithelial neoplasia 10.6
34 staphylococcal toxic shock syndrome 10.6 TNF IL1B
35 peptic esophagitis 10.6 IL1B CXCL8
36 pouchitis 10.5 TLR4 CXCL8
37 kashin-beck disease 10.5 TNF IL1B
38 tungiasis 10.5 TNF CXCL8
39 squamous cell papilloma 10.5
40 papilloma 10.5
41 herpes simplex 10.5
42 cytokine deficiency 10.5
43 campylobacteriosis 10.5 TLR4 IL1B
44 chronic follicular conjunctivitis 10.5 IL1B IL1A
45 trench fever 10.5 TNF TLR4
46 cerebral artery occlusion 10.5 TNF IL1B
47 systemic onset juvenile idiopathic arthritis 10.4 TNF PRF1
48 leukorrhea 10.4
49 congenital cytomegalovirus 10.4 TNF IL1B
50 cardiac sarcoidosis 10.4 TNF CXCL8

Graphical network of the top 20 diseases related to Bacterial Vaginosis:



Diseases related to Bacterial Vaginosis

Symptoms & Phenotypes for Bacterial Vaginosis

MGI Mouse Phenotypes related to Bacterial Vaginosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 IL1A IL1B IL6 NEU1 PEPD PRF1
2 hematopoietic system MP:0005397 9.97 IL1A IL1B IL6 MBL2 NEU1 PEPD
3 homeostasis/metabolism MP:0005376 9.91 IL1A IL1B IL6 MBL2 NEU1 PEPD
4 immune system MP:0005387 9.85 IL1A IL1B IL6 LAP3 MBL2 NEU1
5 integument MP:0010771 9.56 IL1A IL1B IL6 NEU1 PEPD PRF1
6 neoplasm MP:0002006 9.1 IL1A IL1B IL6 PRF1 TLR4 TNF

Drugs & Therapeutics for Bacterial Vaginosis

PubMed Health treatment related to Bacterial Vaginosis: 63

Symptomatic bacterial vaginosis is usually treated using antibiotics to kill the germs. Treatments are available in tablet form or as a suppository or cream for direct application. Another treatment option is suppositories or capsules containing living lactic acid bacteria. These treatments are designed to protect the vaginal flora and restore the correct balance. There is not yet enough evidence on the benefits of this method. Some women also try things like putting tampons that have been soaked in tea tree oil or natural yogurt in their vagina to create a more acidic environment for the vaginal flora, but there has not yet been any research about how effective or safe these kinds of home remedies are.

Drugs for Bacterial Vaginosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Cranberry Approved, Investigational Phase 4
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
7
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
8
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
9
Secnidazole Approved Phase 4 3366-95-8
10
Norethindrone Approved Phase 4 68-22-4 6230
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Metronidazole Approved Phase 4 443-48-1 4173
14
Chlorquinaldol Approved Phase 4 72-80-0
15
Norethindrone enanthate Experimental Phase 4 3836-23-5
16 Alkylating Agents Phase 4
17 Immunologic Factors Phase 4
18 Immune Sera Phase 4
19 14-alpha Demethylase Inhibitors Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Antifungal Agents Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 Steroid Synthesis Inhibitors Phase 4
24 Contraceptive Agents Phase 4
25 Antiviral Agents Phase 4
26 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
27 N-monoacetylcystine Phase 4
28 Respiratory System Agents Phase 4
29 Antidotes Phase 4
30 Free Radical Scavengers Phase 4
31 Antioxidants Phase 4
32 Protective Agents Phase 4
33 cysteine Phase 4
34 Expectorants Phase 4
35 Antitubercular Agents Phase 4
36 Caproate Phase 4
37 Ortho Evra Phase 4
38 Contraceptives, Oral, Combined Phase 4
39 Pharmaceutical Solutions Phase 4
40 Hormones Phase 4
41 Hormone Antagonists Phase 4
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
43 Hawthorn Phase 4
44 Contraceptives, Oral Phase 4
45 Norethindrone Acetate Phase 4
46 Estrogens Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Estradiol 3-benzoate Phase 4
49 Estrogens, Conjugated (USP) Phase 4
50
Formaldehyde Approved, Vet_approved Phase 3 50-00-0 712

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
2 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
3 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
4 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
5 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
6 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
7 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
8 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
9 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
10 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
11 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
12 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
13 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
14 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
15 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
16 Examining the Impact of Tampon Use on the Vaginal Microbiota Completed NCT03346759 Phase 4
17 Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour Completed NCT00568113 Phase 4 acetylcysteine in arm 1
18 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
19 An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra Completed NCT00269620 Phase 4 ethinyl estradiol/etonogestrel vaginal ring;ethinyl estradiol/norelgestromin transdermal contraceptive
20 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
21 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
22 The Efficacy and Safety Study of Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Recruiting NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
23 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
24 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Recruiting NCT03937869 Phase 4 Secnidazole
25 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Recruiting NCT02905890 Phase 4 Norethisterone enantate
26 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
27 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
28 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Active, not recruiting NCT02432404 Phase 4 NuvaRing
29 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
30 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
31 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
32 Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections Unknown status NCT02186145 Phase 3 Association of metronidazole; nystatin and dexamethasone;Flagyl
33 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
34 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
35 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
36 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
37 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
38 Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh Unknown status NCT01572532 Phase 3
39 A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. Completed NCT00229216 Phase 3 Tinidazole
40 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
41 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
42 Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial Completed NCT01160796 Phase 3 placebo;Lcr35®
43 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
44 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
45 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
46 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
47 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
48 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
49 Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi Completed NCT00140764 Phase 3 Metronidazole gel versus placebo gel
50 A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219

Search NIH Clinical Center for Bacterial Vaginosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetic Acid
ACETIC ACID LIQUID
ACETIC ACID,GLACIAL LIQUID
Clindamycin
CLINDAMYCIN PHOSPHATE PWDR
Metronidazole
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Povidone
Secnidazole
Tinidazole

Cochrane evidence based reviews: vaginosis, bacterial

Genetic Tests for Bacterial Vaginosis

Anatomical Context for Bacterial Vaginosis

MalaCards organs/tissues related to Bacterial Vaginosis:

41
Testes, Colon, Cervix, Bone, Skin, Neutrophil, T Cells

Publications for Bacterial Vaginosis

Articles related to Bacterial Vaginosis:

(show top 50) (show all 3654)
# Title Authors PMID Year
1
Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test. 9 38
19647824 2009
2
[Benefits of Affirm VPIII and L-PAP in the diagnosis of bacterial vaginosis]. 9 38
18588815 2008
3
Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. 9 38
18462081 2008
4
MBL2 genetic screening in patients with recurrent vaginal infections. 9 38
18211540 2008
5
Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta. 9 38
17714681 2008
6
The role of mannose-binding lectin gene polymorphisms in women with recurrent bacterial vaginosis. 9 38
17678865 2007
7
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. 9 38
17922400 2007
8
Uterine cervical inflammatory cytokines, interleukin-6 and -8, as predictors of miscarriage in recurrent cases. 9 38
17845205 2007
9
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 9 38
17470593 2007
10
Association of interleukin-1beta and interleukin-1 receptor antagonist polymorphisms with bacterial vaginosis in non-pregnant Italian women. 9 38
17314118 2007
11
Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. 9 38
18273408 2007
12
Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. 9 38
16988245 2006
13
Cervical inflammatory cytokines and other markers in the cervical mucus of pregnant women with lower genital tract infection. 9 38
16307744 2006
14
IL-1beta, IL-6 and IL-8 levels in gyneco-obstetric infections. 9 38
16338780 2005
15
Genetic variation in the interleukin-8 gene promoter and vaginal concentrations of interleukin-8 are not associated with bacterial vaginosis during pregnancy. 9 38
16038986 2005
16
Association between vaginal 70-kd heat shock protein, interleukin-1 receptor antagonist, and microbial flora in mid trimester pregnant women. 9 38
15746691 2005
17
Secondary predictors of preterm labour. 9 38
15715594 2005
18
[Correlation between levels of selected cytokines in cervico-vaginal fluid of women with abnormal vaginal bacterial flora]. 9 38
16494210 2005
19
Does bacterial vaginosis alter the sensitivity of screening tests for Chlamydia trachomatis? An analysis of patient characteristics. 9 38
12869223 2003
20
Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes. 9 38
12517887 2003
21
Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. 9 38
12529421 2003
22
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. 9 38
12388968 2002
23
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis. 9 38
12023767 2002
24
Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. 9 38
12148539 2002
25
Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. 9 38
11845812 2002
26
Vaginal indicators of amniotic fluid infection in preterm labor. 9 38
11165584 2001
27
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. 9 38
10739520 2000
28
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. 9 38
9815222 1998
29
IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in the lower genital tract of pregnant women with bacterial vaginosis. 9 38
9740515 1998
30
Interleukin-1alpha, interleukin-6 and interleukin-8 in cervico/vaginal secretion for screening of preterm birth in twin gestation. 9 38
9654172 1998
31
Evaluation of a fast test to identify the presence of proline aminopeptidase in women with bacterial vaginosis. 9 38
18476142 1997
32
Use of a lactoferrin assay in the differential diagnosis of female genital tract infections and implications for the pathophysiology of bacterial vaginosis. 9 38
8946639 1996
33
Correlation between the clinical diagnosis of bacterial vaginosis and the results of a proline aminopeptidase assay. 9 38
18475340 1994
34
Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. 9 38
8238178 1993
35
Diagnostic microbiology of bacterial vaginosis. 9 38
8357044 1993
36
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. 9 38
1551983 1992
37
Is trichomoniasis often associated with bacterial vaginosis in pregnant adolescents? 9 38
1372472 1992
38
A new proline aminopeptidase assay for diagnosis of bacterial vaginosis. 9 38
1892204 1991
39
Terconazole for the treatment of vulvovaginal candidiasis. 9 38
2277372 1990
40
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. 38
29685081 2019
41
Berberine exhibits antioxidative effects and reduces apoptosis of the vaginal epithelium in bacterial vaginosis. 38
31410167 2019
42
Treatment of bacterial vaginosis before 28 weeks of pregnancy to reduce the incidence of preterm labor. 38
31022300 2019
43
Detection of Methanobrevibacter smithii in vaginal samples collected from women diagnosed with bacterial vaginosis. 38
31127480 2019
44
Association between vaginal washing and detection of Lactobacillus by culture and quantitative PCR in HIV-seronegative Kenyan women: a cross-sectional analysis. 38
30696752 2019
45
Parallel detection of lactobacillus and bacterial vaginosis-associated bacterial DNA in the chorioamnion and vagina of pregnant women at term. 38
29478370 2019
46
Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 Alleviate Bacterial Vaginosis and Osteoporosis in Mice by Suppressing NF-κB-Linked TNF-α Expression. 38
31381476 2019
47
Hormonal Contraception and Vaginal Infections Among Couples Who Are Human Immunodeficiency Virus Serodiscordant in Lusaka, Zambia. 38
31403592 2019
48
Bacterial vaginosis and the risk of human papillomavirus and cervical cancer. 38
31121143 2019
49
An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. 38
31369673 2019
50
Therapeutic effects of probiotic Clostridium butyricum WZ001 on bacterial vaginosis in mice. 38
31102489 2019

Variations for Bacterial Vaginosis

Expression for Bacterial Vaginosis

Search GEO for disease gene expression data for Bacterial Vaginosis.

Pathways for Bacterial Vaginosis

Pathways related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TNF TLR4 NEU1 MBL2 IL6 IL1B
2
Show member pathways
13.34 TNF TLR4 IL6 IL1B IL1A CXCL8
3
Show member pathways
13.07 TNF TLR4 MBL2 IL6 IL1B CXCL8
4
Show member pathways
12.9 TNF TLR4 IL6 IL1B CXCL8
5
Show member pathways
12.86 TNF PRF1 IL6 IL1B IL1A CXCL8
6
Show member pathways
12.75 TNF TLR4 IL6 IL1B CXCL8
7
Show member pathways
12.69 TNF TLR4 IL6 IL1B IL1A
8
Show member pathways
12.59 TNF TLR4 IL6 IL1B IL1A
9
Show member pathways
12.56 TNF TLR4 IL1B IL1A
10
Show member pathways
12.54 TNF IL6 IL1B IL1A
11
Show member pathways
12.34 TNF IL6 IL1B DEFB4A CXCL8
12
Show member pathways
12.3 TNF TLR4 IL6 IL1B IL1A CXCL8
13
Show member pathways
12.28 TNF TLR4 IL6 IL1A CXCL8
14
Show member pathways
12.26 TNF TLR4 IL1B IL1A
15
Show member pathways
12.25 TNF IL6 IL1B IL1A CXCL8
16 12.23 TNF TLR4 IL6 IL1B IL1A
17
Show member pathways
12.22 TNF TLR4 IL1B IL1A
18
Show member pathways
12.22 TNF IL6 IL1B IL1A CXCL8
19 12.17 TNF IL6 IL1B IL1A CXCL8
20
Show member pathways
12.15 TNF IL6 IL1B
21 12.13 TNF TLR4 IL6
22
Show member pathways
12.13 TNF TLR4 IL6 IL1B DEFB4A CXCL8
23 12.11 IL6 IL1A CXCL8
24
Show member pathways
12.07 TNF TLR4 IL6 IL1B
25 12.04 TNF IL1B IL1A
26
Show member pathways
12.04 TNF TLR4 IL6 IL1B
27
Show member pathways
12.03 IL6 IL1B IL1A CXCL8
28 12.01 TNF IL1B IL1A
29 12 TNF IL6 IL1B IL1A CXCL8
30
Show member pathways
11.99 TLR4 IL1B IL1A
31 11.96 IL6 IL1B IL1A CXCL8
32 11.94 TNF IL6 IL1B
33 11.93 TNF TLR4 IL1B CXCL8
34 11.92 TNF IL6 IL1B IL1A
35 11.91 TNF IL6 IL1B IL1A CXCL8
36 11.9 TNF TLR4 IL6 IL1B CXCL8
37
Show member pathways
11.85 TLR4 IL6 CXCL8
38 11.81 TNF TLR4 IL6 IL1B IL1A CXCL8
39 11.79 TLR4 IL6 IL1B IL1A CXCL8
40 11.75 TNF IL6 IL1B
41 11.73 TNF IL6 IL1B
42 11.71 TNF IL6 IL1B CXCL8
43
Show member pathways
11.65 TNF IL6 IL1B IL1A CXCL8
44 11.6 TNF TLR4 IL1A
45 11.55 TNF TLR4 IL1B
46 11.55 TNF TLR4 IL6 IL1B CXCL8
47 11.54 IL6 IL1B IL1A
48 11.51 TNF IL6 IL1B IL1A
49 11.46 TNF TLR4 IL6 IL1B CXCL8
50 11.41 TNF IL6 IL1B

GO Terms for Bacterial Vaginosis

Cellular components related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 TNF MBL2 IL6 IL1B IL1A DEFB4A
2 extracellular region GO:0005576 9.28 TNF PRF1 NEU1 MBL2 IL6 IL1B

Biological processes related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 IL6 IL1B IL1A CXCL8
2 positive regulation of gene expression GO:0010628 9.97 TNF TLR4 IL6 IL1B IL1A
3 defense response to bacterium GO:0042742 9.93 TNF TLR4 MBL2 DEFB4A
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 TNF TLR4 IL1B
5 positive regulation of angiogenesis GO:0045766 9.87 IL1B IL1A CXCL8
6 defense response GO:0006952 9.87 TNF DEFB4A CXCL8
7 activation of MAPK activity GO:0000187 9.85 TNF TLR4 IL1B
8 cytokine-mediated signaling pathway GO:0019221 9.85 TNF IL6 IL1B IL1A CXCL8
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 TNF IL6 IL1B
10 defense response to Gram-negative bacterium GO:0050829 9.83 TLR4 IL6 DEFB4A
11 positive regulation of JNK cascade GO:0046330 9.82 TNF TLR4 IL1B
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 TNF TLR4 IL6 IL1B
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.79 TNF TLR4 IL1B
14 positive regulation of interferon-gamma production GO:0032729 9.77 TNF TLR4 IL1B
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF TLR4 IL1B
16 inflammatory response GO:0006954 9.73 TNF TLR4 IL6 IL1B IL1A CXCL8
17 positive regulation of phagocytosis GO:0050766 9.72 TNF MBL2 IL1B
18 positive regulation of vascular endothelial growth factor production GO:0010575 9.71 IL1B IL1A
19 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.71 TNF IL1B IL1A
20 defense response to Gram-positive bacterium GO:0050830 9.71 TNF MBL2 IL6 DEFB4A
21 positive regulation of mitotic nuclear division GO:0045840 9.7 IL1B IL1A
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.7 TNF TLR4 IL1B
23 embryonic digestive tract development GO:0048566 9.69 TNF CXCL8
24 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.68 TNF IL1B
25 negative regulation of lipid catabolic process GO:0050995 9.68 TNF IL1B
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 TNF IL1B
27 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 TNF IL1B
28 negative regulation of growth of symbiont in host GO:0044130 9.67 TNF MBL2
29 positive regulation of interleukin-8 production GO:0032757 9.67 TNF TLR4 IL1B
30 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.66 IL1B IL1A
31 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.66 TNF TLR4
32 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
33 negative regulation of neurogenesis GO:0050768 9.65 TNF IL6 IL1B
34 positive regulation of chemokine biosynthetic process GO:0045080 9.64 TNF IL1B
35 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
36 ectopic germ cell programmed cell death GO:0035234 9.63 IL1B IL1A
37 response to glucocorticoid GO:0051384 9.62 TNF IL6
38 positive regulation of fever generation GO:0031622 9.62 TNF IL1B
39 positive regulation of interleukin-6 production GO:0032755 9.62 TNF TLR4 IL6 IL1B
40 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
41 positive regulation of chemokine production GO:0032722 9.61 TNF TLR4 IL6
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IL1B
43 fever generation GO:0001660 9.56 IL1B IL1A
44 cellular response to lipopolysaccharide GO:0071222 9.55 TNF TLR4 IL6 IL1B CXCL8
45 positive regulation of glial cell proliferation GO:0060252 9.54 TNF IL6 IL1B
46 positive regulation of neutrophil chemotaxis GO:0090023 9.4 CXCL8
47 chronic inflammatory response to antigenic stimulus GO:0002439 9.3 TNF
48 immune response GO:0006955 9.17 TNF TLR4 IL6 IL1B IL1A DEFB4A
49 positive regulation of neuroinflammatory response GO:0150078 9.13 TNF IL6 IL1B

Molecular functions related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 aminopeptidase activity GO:0004177 9.16 PEPD LAP3
2 cytokine activity GO:0005125 9.02 TNF IL6 IL1B IL1A CXCL8
3 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1A

Sources for Bacterial Vaginosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....